New study reveals molecular mechanism in Alzheimer’s disease

A research team at the Institute of Neurosciences of the University of Barcelona (UBneuro) has led a study describing a new molecular mechanism that affects RNA processing and alters the process of protein synthesis in the brains of Alzheimer’s patients.

QL-401 by QLSF Biotherapeutics for Refractory Acute Myeloid Leukemia: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

January 6, 2025

IG Live October 23: Life in the Fast Lane With FDA’s Accelerated Approvals

The FDA’s accelerated approval pathway is a hot topic in health policy. Recent controversies include the approval of aducanumab (Aduhelm) for Alzheimer’s disease and the

October 20, 2023

Glaukos wins FDA approval for drug-releasing eye implant to treat glaucoma

Dive Brief: Glaukos Corporation received Food and Drug Administration approval for a drug-releasing implant that is designed to reduce intraocular pressure in patients with ocular

December 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.